Gelonghui, December 19 - FOSUN PHARMA (600196.SH) announced that on December 19, 2024, its holding subsidiary HENLIUS signed a "Cooperation and License Agreement" with Palleon. According to the agreement, both parties will collaborate on the global development of Palleon’s investigational product E-602 and related combination therapy solutions within the field (i.e., for the treatment of human diseases) based on their respective patents and proprietary technologies, and will carry out commercialization in their respective licensed areas.
复星医药(600196.SH)：控股子公司签署许可协议
FOSUN PHARMA (600196.SH): A subsidiary has signed a licensing agreement.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th